Gene: MYO3A
Official Full Name: myosin IIIAprovided by HGNC
Gene Summary: The protein encoded by this gene belongs to the myosin superfamily. Myosins are actin-dependent motor proteins and are categorized into conventional myosins (class II) and unconventional myosins (classes I and III through XV) based on their variable C-terminal cargo-binding domains. Class III myosins, such as this one, have a kinase domain N-terminal to the conserved N-terminal motor domains and are expressed in photoreceptors. The protein encoded by this gene plays an important role in hearing in humans. Three different recessive, loss of function mutations in the encoded protein have been shown to cause nonsyndromic progressive hearing loss. Expression of this gene is highly restricted, with the strongest expression in retina and cochlea. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO21902 | MYO3A Knockout cell line (HEK293) | Human | MYO3A | 1:3~1:6 | Negative | Online Inquiry |
MYO3A Gene Knockout Cell Lines are customized cellular models engineered to specifically lack the functional MYO3A gene, which encodes a member of the myosin protein family implicated in numerous cellular processes, including intracellular transport and signal transduction. By employing CRISPR-Cas9 gene-editing technology, these cell lines facilitate precise gene knockout, allowing for the study of MYO3A-related pathways and its role in various physiological and pathological conditions.
The primary mechanism of action for MYO3A Gene Knockout Cell Lines involves the targeted disruption of the MYO3A gene, leading to the production of cells that exhibit deficient myosin motor activity. This alteration provides researchers with an invaluable tool to investigate the function of MYO3A in diverse processes such as cell migration, adhesion, and differentiation, as well as its potential implications in diseases like cancer and neurological disorders.
The scientific importance of MYO3A Gene Knockout Cell Lines extends to both research and clinical settings, enabling advanced studies on the mechanistic underpinnings of diseases linked to MYO3A dysfunction. They are particularly beneficial for pharmaceutical development, serving as a platform for drug screening and efficacy testing targeting MYO3A-related pathways.
One of the unique advantages of our MYO3A Gene Knockout Cell Lines is their high specificity and reproducibility compared to traditional gene silencing methods like siRNA or shRNA, which can lead to off-target effects and inconsistent results. Additionally, these knockout models have been fully validated, ensuring reliable and robust experimental outcomes for users.
Researchers and clinicians seeking to elucidate the functions of the MYO3A gene will find significant value in these knockout cell lines, as they allow for in-depth investigation into the gene's contribution to cellular processes and disease mechanisms. By using our product, users can generate meaningful insights and accelerate their research timelines.
Our company prides itself on extensive expertise in genetic engineering and cell line development, offering a range of high-quality biological products tailored to meet the rigorous demands of scientific research. By providing precisely engineered models like MYO3A Gene Knockout Cell Lines, we strive to empower life scientists and clinicians in their quest for discovery and innovation.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.